Giacomo Loseto

Bari, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances

Published: April 16, 2026

SPINK2 in hematopoiesis and cancer: Biology and clinical implications.

SPINK2 in hematopoiesis and cancer: Biology and clinical implications.

Journal: Cell death discovery

Published: March 24, 2026

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

Journal: BMC health services research

Published: October 28, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances

Published: October 15, 2025

SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia.

SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia.

Journal: Cell death discovery

Published: October 14, 2025

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Journal: Annals of hematology

Published: October 13, 2025

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective.

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective.

Journal: Hematological oncology

Published: June 25, 2025

Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.

Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.

Journal: Haematologica

Published: March 20, 2025

A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes.

A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes.

Journal: Haematologica

Published: February 22, 2024

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Journal: Hematological oncology

Published: November 15, 2023

Showing 1-12 of 50

Last Updated: 09/26/2026